TRACON Pharmaceuticals

$9.04
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.64 (+7.62%) Today
$0.00 (0.00%) As of 9:26 PM UTC after-hours

Why Robinhood?

You can buy or sell TCON and other stocks, options, and ETFs commission-free!

About TCON

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA. The listed name for TCON is TRACON Pharmaceuticals, Inc. Common Stock.

CEO
Charles P. Theuer
Employees
19
Headquarters
San Diego, California
Founded
2004
Market Cap
123.71M
Price-Earnings Ratio
Dividend Yield
Average Volume
1.87M
High Today
$10.11
Low Today
$8.58
Open Price
$8.68
Volume
1.17M
52 Week High
$10.11
52 Week Low
$0.95

Collections

TCON Earnings

-$1.66
-$1.11
-$0.55
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
per share
Actual
Available Nov 10, After Hours

You May Also Like